Insulin aspart, recombinant Subcutaneous and Zevalin In-111
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Zevalin In-111 and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: ibritumomab
Brand name: Y-90 Zevalin, In-111 Zevalin
Synonyms: Zevalin In-111 (Intravenous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Zevalin Y-90
- Insulin aspart, recombinant Subcutaneous-Zflex
- Insulin aspart, recombinant Subcutaneous-Zgesic
- Insulin aspart, recombinant Subcutaneous-Ziac
- Insulin aspart, recombinant Subcutaneous-Ziagen
- Insulin aspart, recombinant Subcutaneous-Ziagen (Abacavir Oral Solution)
- Zevalin In-111-Insulin degludec
- Zevalin In-111-Insulin Degludec (U-100) Prefilled Pens
- Zevalin In-111-Insulin Degludec (U-100) Vials
- Zevalin In-111-Insulin Degludec (U-200) Prefilled Pens
- Zevalin In-111-Insulin degludec and liraglutide
- Zevalin In-111-Insulin degludec and liraglutide Subcutaneous